Head-to-head · WeighScore
Remi Meds vs WeightRx
The verdict
WeightRx takes it — 72.1/100 to 48.4/100.
WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Remi Meds | WeightRx |
|---|---|---|
| WeighScore | 48.4/100 | 72.1/100 |
| Grade | C | C |
| Scorecard rank | #539 | #97 |
| Semaglutide | $249/mo (0.25 mg dose, compounded) | $250/mo (compounded) |
| Tirzepatide | $349/mo (2.25 mg dose, compounded) | $83/mo (term not published, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #539 · C
Strengths
- Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
- LegitScript verification badge on the homepage
- Publishes 503A FDCA compliance language on the tirzepatide page
- Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
- Operating corporate entity disclosed (T-C Health Co)
Where it loses points
- No named medical director, founder, or physician on any public page
- States served not listed — 'nationwide' claim with no per-state detail
- Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
- Year founded and corporate history are opaque
- Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure
Graded #97 · C
Strengths
- The tirzepatide figure is published up front, and it is genuinely low against the field
- Both molecules are offered
- No membership charge is advertised alongside the medication rate
Where it loses points
- The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
- Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
- Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
- No dose strength is published anywhere, so what the $83 buys is not stated
- The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.